股票简称：奥翔药业 股票代码：603229 中国·浙江·临海 2024 年 5 月 20 日 浙江奥翔药业股份有限公司 2023 年年度股东大会议程 浙江奥翔药业股份有限公司 2023 年年度股东大会 会议资料 一、会议时间 现场会议时间：2024年5月20日14点00分； 网络投票时间：采用上海证券交易所网络投票系统，通过交易系统投票平台 的投票时间为股东大会召开当日的交易时间段，即9:15-9:25,9:30-11:30， 13:00-15:00；通 过 互联网 投票 平台 的 投票时 间为 股东 大 会召开 当日的 9:15-15:00。 二、现场会议地点 浙江省化学原料药基地临海园区东海第四大道5号公司新办公楼一楼会议室 三、会议主持人 公司董事长：郑志国先生 四、会议议程 （一）主持人宣布会议开始； （二）主持人介绍本次会议出席情况； （三）宣读奥翔药业2023年年度股东大会会议须知； （四）宣读股东大会审议议案： 1、《关于 2023 年度董事会工作报告的议案》； 2、《关于 2023 年度监事会工作报告的议案》； 3、《关于 2023 年度财务决算报告的议案》； 4、《关于 2023 年度利润分 ...

大家好欢迎参加张双英药翱翔药业2023年报和2024易记报业绩交流会目前所有参会者均处于静音状态下面开始播报免责声明声明播报完毕后主持人可直接发言谢谢 本次电话会议仅面向招商证券的专业投资机构客户或受邀客户会议嘉宾发言内容仅代表其个人观点所有信息或观点不构成投资建议未经招商证券事先书面许可任何机构或个人严禁录音、制作纪要、转发、转载、传播、复制、编辑、修改等涉嫌违反上述情形的我们将保留一切法律权利感谢您的理解和支持,谢谢 好的各位投资者下午好我是招商医药许飞飞和我一起主持的还有团队成员侯彪以及就是我们在今天呢也非常荣幸的就是请到了就是公司的领导就是董事长郑总董事会秘书殷总和证券事务代表王总和我们进行奥祥药业的最新近况的交流与我们共同主持的券商还包括华创太平洋信达新业东吴国金中泰的各位友商老师们 那我们也可以看到说澳大利亚其实也是发布了一个非常亮眼的成绩在Q1来看的话在23年Q1的高基础上依然实现了一个比较亮眼的增长那我们先把话筒交给董事长郑总请他为我们带来公司的近况的经营更新谢谢谢谢小蜀以及其他的各位专商朋友 线上的各位投资者朋友关于奥祥的就是2023那个这里有两个一个是年报还有一个是2024的季报年报的话呃 ...

在法律允许的情况下，国金证券的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供多种金融服务。 本报告并非意图发送、发布给在当地法律或监管规则下不允许向其发送、发布该研究报告的人员。国金证券并不因收件人收到本报告而视其为国金证券的客 户。本报告对于收件人而言属高度机密，只有符合条件的收件人才能使用。根据《证券期货投资者适当性管理办法》，本报告仅供国金证券股份有限公司客户中风 险评级高于 C3 级(含 C3 级）的投资者使用；本报告所包含的观点及建议并未考虑个别客户的特殊状况、目标或需要，不应被视为对特定客户关于特定证券或金融 工具的建议或策略。对于本报告中提及的任何证券或金融工具，本报告的收件人须保持自身的独立判断。使用国金证券研究报告进行投资，遭受任何损失，国金证 券不承担相关法律责任。 若国金证券以外的任何机构或个人发送本报告，则由该机构或个人为此发送行为承担全部责任。本报告不构成国金证券向发送本报告机构或个人的收件人提供 投资建议，国金证券不为此承担任何责任。 此报告仅限于中国境内使用。国金证券版权所有，保留一切权利。 【小程序】 国金证券研究服务 【公众号】 ...

目 录 | 一、审计报告……………………………………………………… 第 1—6 | | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… | 第 | 7 页 | | （二）母公司资产负债表………………………………………… | 第 | 8 页 | | （三）合并利润表………………………………………………… | 第 | 9 页 | | （四）母公司利润表………………………………………………第 | | 10 页 | | （五）合并现金流量表……………………………………………第 | | 11 页 | | （六）母公司现金流量表…………………………………………第 | | 12 页 | | （七）合并所有者权益变动表……………………………………第 | | 13 页 | | （八）母公司所有者权益变动表…………………………………第 | | 14 页 | | | | 审 计 报 告 天健审〔2024〕3163 号 浙江奥翔药业股份有限公司全体股东： 一、审计意见 我们审计了浙江奥 ...

浙江奥翔药业股份有限公司全体股东： 浙江奥翔药业股份有限公司 2023 年度内部控制评价报告 公司代码：603229 公司简称：奥翔药业 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能 ...

Financial Performance - The company's operating revenue for 2023 was CNY 816,765,083.27, representing a year-over-year increase of 6.83% compared to CNY 764,547,389.04 in 2022[22]. - The net profit attributable to shareholders of the listed company reached CNY 253,901,967.43, up 7.87% from CNY 235,375,827.46 in the previous year[22]. - The net cash flow from operating activities significantly increased by 84.00%, totaling CNY 221,847,783.71 compared to CNY 120,567,033.68 in 2022[22]. - The total assets of the company at the end of 2023 were CNY 2,951,571,189.46, reflecting a 27.48% increase from CNY 2,315,330,188.78 at the end of 2022[22]. - The basic earnings per share for 2023 was CNY 0.43, a 4.88% increase from CNY 0.41 in 2022[23]. - The weighted average return on equity decreased to 12.73%, down 4.63 percentage points from 17.36% in 2022[23]. - The company reported a net profit of CNY 93,672,808.45 in the first quarter of 2023, with a decline in the second quarter to CNY 66,523,939.88[25]. - The company's net assets attributable to shareholders increased by 46.57% to CNY 2,141,576,554.10 at the end of 2023 from CNY 1,461,140,520.64 at the end of 2022[22]. - The company achieved operating revenue of 816.77 million yuan, a year-on-year increase of 6.83%[33]. - The net profit attributable to shareholders was 253.90 million yuan, reflecting a year-on-year growth of 7.87%[33]. Research and Development - R&D investment reached 78.06 million yuan, accounting for 9.56% of operating revenue[36]. - The company has established a research and development team of 241 members, including PhDs and Masters, to enhance its R&D capabilities[36]. - The company emphasizes R&D as a key driver for growth, focusing on high-end, intelligent, and green transformation in the pharmaceutical industry[32]. - The company is leveraging partnerships with renowned universities and research institutions to boost R&D efficiency and innovation[35]. - The company has a significant focus on R&D, with a capitalized R&D ratio of 0% and a net asset ratio of 3.64%[104]. - The company plans to enhance its R&D capabilities by building a comprehensive R&D system and collaborating with renowned universities and research institutions[121]. - The company reported R&D expenditures of 78.06 million RMB, accounting for 9.56% of operating revenue[104]. - The company has multiple drug products under review, including 3 products for pulmonary arterial hypertension and 5 for ophthalmic use, with various approval statuses across regions[100]. Market and Industry Trends - The global pharmaceutical market is projected to grow from approximately $1.48 trillion in 2022 to $1.9 trillion by 2027, with a CAGR of 3-6%[39]. - The aging population in China is a significant driver for the pharmaceutical market, with the population aged 65 and above increasing from 140 million in 2014 to 220 million in 2023[40]. - The global pharmaceutical expenditure was approximately $1.48 trillion in 2022, with a projected CAGR of 3-6%, reaching $1.9 trillion by 2027[87]. - China's pharmaceutical market size was ¥1,554.1 billion in 2022, expected to reach ¥2,624.5 billion by 2030, with the chemical drug segment accounting for 50% of the total market[43]. - The company has identified a trend of increasing demand for pharmaceutical formulations due to global aging and rising healthcare awareness[117]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[4]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the annual report's authenticity[9]. - The company emphasizes the importance of independent governance and compliance with legal regulations in its operations and decision-making processes[128]. - The company has a clear governance structure with no significant differences from regulatory requirements[130]. - The company is focused on maintaining independence from its controlling shareholders and has not reported any related issues[130]. - The company has not faced any delisting risks during the reporting period[188]. - The company has not reported any significant changes in its integrity status or that of its major stakeholders[189]. Environmental Responsibility - The company invested RMB 23.426 million in environmental protection during the reporting period[171]. - Aoxiang Pharmaceutical is listed as a key pollutant discharge unit by the environmental protection department for 2023[172]. - The total non-methane hydrocarbon emissions for 2023 were 1.82 tons, with an average emission concentration of 16.92 mg/m³[172]. - The wastewater discharge for 2023 was 168,342.76 tons, with a total allowable discharge of 268,780 tons, and an average chemical oxygen demand concentration of 218.8 mg/L[172]. - Aoxiang Pharmaceutical has established a complete environmental risk emergency mechanism, with an emergency plan filed on November 15, 2023[176]. - The company has no administrative penalties for environmental issues during the reporting period[178]. - Aoxiang Pharmaceutical has implemented a self-monitoring plan for environmental pollutants, with all monitored indicators meeting discharge standards[177]. Shareholder and Capital Management - The company plans to distribute a cash dividend of RMB 1.29 per 10 shares, totaling RMB 76,505,951.18, and to increase its share capital by 237,227,756 shares through a capital reserve transfer, raising total shares from 593,069,389 to 830,297,145[5]. - The company reported a significant increase in shareholding for Chairman and General Manager Zheng Zhiguo, from 214,506,991 shares at the beginning of the year to 300,309,788 shares, an increase of 40%[133]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 7.5806 million yuan[144]. - The company has a structured process for determining the remuneration of its board members, ensuring alignment with performance metrics[144]. - The company has proposed to change its corporate type and has submitted relevant resolutions for approval[149]. Operational Efficiency and Cost Management - The company is enhancing its production management and cost control measures to improve operational efficiency[36]. - The management team is committed to enhancing operational efficiency and cost management to improve overall financial performance[136]. - The company is focusing on developing a one-stop service model by vertically integrating CRO/CDMO/CMO services across all stages of the pharmaceutical development process[48]. - The company is investing in advanced technologies to enhance drug development processes, including enzyme catalysis and continuous flow reaction technologies, to optimize production efficiency and reduce costs[49]. Risk Management - The company has outlined potential risks in the management discussion and analysis section, advising investors to be cautious[10]. - The company faces risks related to product quality, requiring compliance with GMP and cGMP certifications for domestic and export sales[123]. - Environmental risks are heightened due to complex chemical processes that generate waste, necessitating increased investment in environmental compliance[124]. - The company is exposed to exchange rate fluctuations due to a significant portion of revenue being generated from exports settled in foreign currencies[125].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 300,914,417.10, representing a year-on-year increase of 14.61%[4] - The net profit attributable to shareholders for the same period was CNY 112,480,834.45, reflecting a growth of 20.08% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 108,489,854.53, which is an increase of 17.69% year-on-year[4] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.19, marking an increase of 18.75%[4] - Total operating revenue for Q1 2024 reached ¥300,914,417.10, a 14.6% increase from ¥262,549,690.48 in Q1 2023[17] - Net profit attributable to shareholders for Q1 2024 was ¥112,480,834.45, representing a 20% increase compared to ¥93,672,808.45 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.19, up from ¥0.16 in Q1 2023[18] Cash Flow - The net cash flow from operating activities decreased by 39.98%, primarily due to a relative reduction in received payments compared to the same period last year[7] - Cash flow from operating activities in Q1 2024 was ¥166,699,040.56, down from ¥208,507,860.64 in Q1 2023, indicating a decrease of 20.1%[19] - The net cash flow from operating activities for Q1 2024 was ¥26,983,529.17, a decrease of 40% compared to ¥44,955,913.77 in Q1 2023[20] - The total cash inflow from financing activities was ¥70,000,000.00, significantly lower than ¥573,933,781.92 in the previous year[21] - The net cash flow from investing activities was -¥21,275,021.86, compared to -¥81,121,541.50 in Q1 2023, indicating a reduced outflow[20] - The total cash outflow for operating activities was ¥179,967,435.29, compared to ¥243,010,208.91 in the previous year, showing a decrease in cash expenses[20] - The company experienced a negative impact of -¥691,997.96 from exchange rate fluctuations on cash and cash equivalents[21] - The net increase in cash and cash equivalents for Q1 2024 was -¥14,742,889.83, contrasting sharply with an increase of ¥501,884,558.67 in Q1 2023[21] Assets and Liabilities - The total assets at the end of the reporting period amounted to CNY 3,045,057,290.07, up 3.17% from the end of the previous year[5] - The company's current assets totaled RMB 1,762,690,515.89, up from RMB 1,674,726,430.55, indicating an increase of about 5.2%[12] - Accounts receivable rose significantly to RMB 291,549,334.69 from RMB 132,750,843.88, representing an increase of approximately 119.9%[12] - Inventory decreased to RMB 311,211,637.19 from RMB 365,179,023.26, showing a decline of about 14.8%[12] - The company's total liabilities were not explicitly stated, but current liabilities included short-term borrowings of RMB 300,361,549.62, which remained relatively stable compared to RMB 300,259,888.90[13] - Total liabilities as of Q1 2024 amounted to ¥781,236,851.23, a decrease from ¥809,994,635.36 in the previous year[14] - The company’s non-current assets totaled RMB 1,282,366,774.18, a slight increase from RMB 1,276,844,758.91, reflecting a growth of about 0.4%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,488[9] - There were no significant changes reported in the top 10 shareholders or their shareholdings during the reporting period[10] Expenses and Other Financial Metrics - Operating costs for Q1 2024 were ¥167,168,222.81, up 10.9% from ¥150,656,558.62 in Q1 2023[17] - Research and development expenses for Q1 2024 were ¥23,250,646.98, an increase of 8.3% from ¥21,462,162.83 in Q1 2023[17] - The company reported a credit impairment loss of ¥7,737,852.29 in Q1 2024, compared to ¥2,691,497.15 in Q1 2023, indicating a significant increase in credit risk[17] - Deferred income tax liabilities rose to ¥2,659,507.82 in Q1 2024 from ¥2,073,627.22 in Q1 2023, showing an increase of 28.2%[14] - The company paid ¥62,363,523.90 in employee compensation, which is an increase from ¥59,126,401.00 in Q1 2023[20]

证券代码：603229 证券简称：奥翔药业 公告编号：2024-016 浙江奥翔药业股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 5 月 9 日(星期四) 下午 15:00-16:00 会议召开 地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 4 月 29 日(星期一) 至 5 月 8 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 board@ausunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 浙江奥翔药业股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日发 布公司 2023 年度报告及 2024 年第一季度报告，为便于广大投资者更全面深入地 了解公司 2023 年度及 2024 年第一 ...

证券代码：603229 证券简称：奥翔药业 公告编号：2024-009 浙江奥翔药业股份有限公司 关于公司 2024 年度对外担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 被担保人名称: 浙江奥翔药业股份有限公司（以下简称"公司"或"奥 翔药业"）全资子公司浙江麒正药业有限公司（以下简称"麒正药业"）。 本次担保金额及已实际为其提供的担保余额：本次预计继续为其提供担 保金额不超过人民币 35,000.00 万元；截至本公告披露日，已实际为其提供的担 保余额为人民币 35,000.00 万元（过往协议仍在有效期）。 一、担保情况概述 （一）担保基本情况 公司董事会提请股东大会授权公司董事长及其授权人士在公司 2023 年年度 股东大会审议通过之日起至 2024 年年度股东大会召开日期限内，在上述担保额 度范围内，全权办理提供担保的具体事项。 （二）本次担保事项履行的内部决策程序 本次担保是否有反担保：否 对外担保逾期的累计数量：无对外担保逾期情况 本次担保事项尚需提交公司股东大会审议 为满足 ...

浙江奥翔药业股份有限公司 证券代码：603229 证券简称：奥翔药业 公告编号：2024-004 第四届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江奥翔药业股份有限公司（以下简称"公司"）第四届监事会第二次会议 于 2024 年 4 月 25 日在浙江省化学原料药基地临海园区东海第四大道 5 号公司新 办公楼一楼会议室以现场的方式召开。会议通知已于 2024 年 4 月 15 日以专人送 达或电子邮件方式送交公司全体监事。本次会议应参加监事 3 人，实际参加监事 3 人，会议由监事会主席徐海燕女士主持。会议的通知、召集、召开和表决程序 符合《中华人民共和国公司法》《公司章程》等有关法律、法规的规定。 二、监事会会议审议情况 （二）审议通过《关于 2023 年度财务决算报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 （三）审议通过《关于 2023 年度利润分配及资本公积金转增股本预案的议案》 经全体监事认真审议并表决，一致 ...